The U.S. National Institutes of Health on Wednesday rejected a nonprofit company’s challenge to Abbott Laboratories Inc.'s (NYSE:ABT - News) 400 percent price hike on a key AIDS medicine. Washington-based Essential Inventions had asked the government for a license to produce cheaper, generic copies of the drug, Norvir, before the patent expires in 2014. The group argued Norvir was developed with support from taxpayer funds and was being sold at an unreasonable price.
